title: Ketamine, not fentanyl, suppresses pain-related magnetic fields associated with trigeminally innervated area following CO2 laser stimulation.
abstract: A variety of pharmacological agents are clinically used to treat pain-related diseases, including in the orofacial region. The effects of analgesics upon cerebral sites responsible for pain perception have yet to be determined. The aim of the present study was to examine the effects of ketamine, an N-methyl-d-aspartate (NMDA) antagonist, and fentanyl, a narcotic analgetic, on pain-related somatosensory-evoked magnetic fields (pain-SEFs) induced by CO(2) laser stimulation of the trigeminally innervated area. Two peaks with latencies of approximately 120 and 200 ms were observed in pain-SEFs after CO(2) laser stimulation. Peaks with approximately 120 ms latency were detected in the bilateral secondary somatosensory cortices. Amplitude of pain-SEFs after CO(2) laser stimulation increased in an intensity-dependent manner. Ketamine suppressed amplitude and prolonged latency of pain-SEFs, whilst fentanyl did not. This suggests that ketamine inhibits NMDA receptor-mediated neurotransmission in a pain input pathway to the cerebral cortex, thereby exerting an analgesic effect. Fentanyl, which acts via opioid receptors, is believed to act differently to ketamine in the pain input process.
authors.affiliation: Laboratory of Brain Research, Oral Health Science Center, Tokyo Dental College, Mihama-ku, Chiba 261-8502, Japan.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Matsuura
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Shibukawa
authors.forename: Motoichiro
authors.initials: M
authors.lastname: Kato
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Ichinohe
authors.forename: Takashi
authors.initials: T
authors.lastname: Suzuki
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Kaneko
mesh_terms: D000328:Adult; D000700:Analgesics / Q000494:pharmacology*; D005157:Facial Pain / Q000188:drug therapy* / Q000209:etiology; D005283:Fentanyl / Q000494:pharmacology*; D006801:Humans; D007649:Ketamine / Q000494:pharmacology*; D054020:Lasers, Gas / Q000009:adverse effects*; D015225:Magnetoencephalography; D008297:Male; D009619:Nociceptors / Q000187:drug effects / Q000502:physiology; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000378:metabolism; D012867:Skin / Q000294:innervation; D013003:Somatosensory Cortex / Q000187:drug effects* / Q000502:physiology; D014276:Trigeminal Nerve / Q000502:physiology
chemical_list: D000700:Analgesics; D016194:Receptors, N-Methyl-D-Aspartate; D007649:Ketamine; D005283:Fentanyl